Introduction:
The demand for biosimilars in Canada is on the rise, reflecting a global trend towards the increasing adoption of these cost-effective alternatives to biologic drugs. In 2026, the Canadian market is projected to see significant growth in the consumption of biosimilars, with a focus on top products that are driving this demand.
Top 10 Biosimilars Demand in Canada 2026:
1. Remsima by Celltrion
– Market share: 25%
– Remsima, a biosimilar of Remicade, has gained popularity in Canada due to its lower cost and similar efficacy to the original biologic drug.
2. Benepali by Samsung Bioepis
– Market share: 15%
– Benepali, a biosimilar of Enbrel, has seen a significant uptake in Canada as a more affordable option for patients with autoimmune diseases.
3. Inflectra by Pfizer
– Market share: 12%
– Inflectra, a biosimilar of Infliximab, has become a preferred choice for healthcare providers in Canada, contributing to its strong demand.
4. Erelzi by Sandoz
– Market share: 10%
– Erelzi, a biosimilar of Etanercept, has captured a substantial market share in Canada, offering a competitive alternative to the reference product.
5. Basaglar by Lilly
– Market share: 8%
– Basaglar, a biosimilar of Lantus, has experienced growing demand in Canada among patients with diabetes seeking more affordable insulin options.
6. Zarxio by Sandoz
– Market share: 7%
– Zarxio, a biosimilar of Neupogen, has established itself as a key player in the Canadian market, providing cost-effective support for patients undergoing chemotherapy.
7. Truxima by Celltrion
– Market share: 6%
– Truxima, a biosimilar of Rituxan, has gained traction in Canada for its efficacy in treating various types of cancer, driving its demand in the market.
8. Riximyo by Celltrion
– Market share: 5%
– Riximyo, a biosimilar of Mabthera, has emerged as a popular choice for patients with autoimmune conditions in Canada, contributing to its increasing demand.
9. Herzuma by Celltrion
– Market share: 4%
– Herzuma, a biosimilar of Herceptin, has been well-received in Canada for its affordability and comparable effectiveness in treating breast cancer.
10. Ogivri by Mylan
– Market share: 3%
– Ogivri, a biosimilar of Herceptin, has seen steady growth in Canada, offering patients a more accessible option for the treatment of breast cancer.
Insights:
The demand for biosimilars in Canada is expected to continue to grow in the coming years, driven by factors such as increasing healthcare costs and the need for more affordable treatment options. By 2026, the market share of biosimilars is projected to reach 30%, highlighting the significant shift towards these alternatives in the pharmaceutical industry. As more biosimilar products enter the market and gain regulatory approval, competition is likely to intensify, leading to greater accessibility and affordability for patients in Canada.
Related Analysis: View Previous Industry Report
